Literature DB >> 31776283

The IFNL4 Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation.

Hao Zhou1, Michelle Møhlenberg1, Ewa Terczyńska-Dyla2, Kasper Grønbjerg Winther1, Nanna Hougaard Hansen1, Johan Vad-Nielsen2, Laura Laloli3,4,5,6, Ronald Dijkman3,4,6, Anders Lade Nielsen2, Hans Henrik Gad1, Rune Hartmann7.   

Abstract

Interferon lambda 4 (IFN-λ4) is a recently identified enigmatic member of the interferon (IFN) lambda family. Genetic data suggest that the IFNL4 gene acts in a proviral and anti-inflammatory manner in patients. However, the protein is indistinguishable in vitro from the other members of the interferon lambda family. We have investigated the gene regulation of IFNL4 in detail and found that it differs radically from that of canonical antiviral interferons. Being induced by viral infection is a defining characteristic of interferons, but viral infection or overexpression of members of the interferon regulatory factor (IRF) family of transcription factors only leads to a minute induction of IFNL4 This behavior is evolutionarily conserved and can be reversed by inserting a functional IRF3 binding site into the IFNL4 promoter. Thus, the regulation of the IFNL4 gene is radically different and might explain some of the atypical phenotypes associated with the IFNL4 gene in humans.IMPORTANCE Recent genetic evidence has highlighted how the IFNL4 gene acts in a counterintuitive manner, as patients with a nonfunctional IFNL4 gene exhibit increased clearance of hepatitis C virus (HCV) but also increased liver inflammation. This suggests that the IFNL4 gene acts in a proviral and anti-inflammatory manner. These surprising but quite clear genetic data have prompted an extensive examination of the basic characteristics of the IFNL4 gene and its gene product, interferon lambda 4 (IFN-λ4). We have investigated the expression of the IFNL4 gene and found it to be poorly induced by viral infections. A thorough investigation of the IFNL4 promoter revealed a highly conserved and functional promoter, but also one that lacks the defining characteristic of interferons (IFNs), i.e., the ability to be effectively induced by viral infections. We suggest that the unique function of the IFNL4 gene is related to its noncanonical transcriptional regulation.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  hepatitis C virus; interferons; transcriptional regulation

Mesh:

Substances:

Year:  2020        PMID: 31776283      PMCID: PMC7022339          DOI: 10.1128/JVI.01535-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients.

Authors:  Brad R Rosenberg; Catherine A Freije; Naoko Imanaka; Spencer T Chen; Jennifer L Eitson; Rachel Caron; Skyler A Uhl; Marija Zeremski; Andrew Talal; Ira M Jacobson; Charles M Rice; John W Schoggins
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

2.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.

Authors:  Ewa Terczyńska-Dyla; Stephanie Bibert; Francois H T Duong; Ilona Krol; Sanne Jørgensen; Emilie Collinet; Zoltán Kutalik; Vincent Aubert; Andreas Cerny; Laurent Kaiser; Raffaele Malinverni; Alessandra Mangia; Darius Moradpour; Beat Müllhaupt; Francesco Negro; Rosanna Santoro; David Semela; Nasser Semmo; Markus H Heim; Pierre-Yves Bochud; Rune Hartmann
Journal:  Nat Commun       Date:  2014-12-23       Impact factor: 14.919

3.  Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.

Authors:  Miyako Murakawa; Yasuhiro Asahina; Fukiko Kawai-Kitahata; Mina Nakagawa; Sayuri Nitta; Satoshi Otani; Hiroko Nagata; Shun Kaneko; Yu Asano; Tomoyuki Tsunoda; Masato Miyoshi; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Yasuhito Tanaka; Sayuki Iijima; Kaoru Tsuchiya; Namiki Izumi; Shuji Tohda; Mamoru Watanabe
Journal:  J Med Virol       Date:  2017-02-27       Impact factor: 2.327

4.  Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Authors:  Salvatore Petta; Luca Valenti; Antonino Tuttolomondo; Paola Dongiovanni; Rosaria Maria Pipitone; Calogero Cammà; Daniela Cabibi; Vito Di Marco; Anna Ludovica Fracanzani; Sara Badiali; Valerio Nobili; Silvia Fargion; Stefania Grimaudo; Antonio Craxì
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

5.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

Review 6.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

7.  Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells.

Authors:  C Lauber; G Vieyres; E Terczyńska-Dyla; R Dijkman; H H Gad; H Akhtar; R Geffers; F W R Vondran; V Thiel; L Kaderali; T Pietschmann; R Hartmann
Journal:  Genes Immun       Date:  2015-06-11       Impact factor: 2.676

Review 8.  Guarding the frontiers: the biology of type III interferons.

Authors:  Andreas Wack; Ewa Terczyńska-Dyla; Rune Hartmann
Journal:  Nat Immunol       Date:  2015-08       Impact factor: 25.606

9.  EWS and FUS bind a subset of transcribed genes encoding proteins enriched in RNA regulatory functions.

Authors:  Yonglun Luo; Jenny Blechingberg; Ana Miguel Fernandes; Shengting Li; Tue Fryland; Anders D Børglum; Lars Bolund; Anders Lade Nielsen
Journal:  BMC Genomics       Date:  2015-11-14       Impact factor: 3.969

10.  IFNL4-ΔG is associated with prostate cancer among men at increased risk of sexually transmitted infections.

Authors:  Tsion Zewdu Minas; Wei Tang; Cheryl J Smith; Olusegun O Onabajo; Adeola Obajemu; Tiffany H Dorsey; Symone V Jordan; Obadi M Obadi; Bríd M Ryan; Ludmila Prokunina-Olsson; Christopher A Loffredo; Stefan Ambs
Journal:  Commun Biol       Date:  2018-11-14
View more
  5 in total

Review 1.  Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases.

Authors:  Jonathan W Wallace; David A Constant; Timothy J Nice
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

2.  Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 Proteins.

Authors:  Cuncai Guo; Dorothee Reuss; Jonathon D Coey; Swathi Sukumar; Benjamin Lang; John McLauchlan; Steeve Boulant; Megan L Stanifer; Connor G G Bamford
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

3.  Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling.

Authors:  Mariia Lunova; Jan Kubovciak; Barbora Smolková; Mariia Uzhytchak; Kyra Michalova; Alexandr Dejneka; Pavel Strnad; Oleg Lunov; Milan Jirsa
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

4.  Distinct molecular phenotypes involving several human diseases are induced by IFN-λ3 and IFN-λ4 in monocyte-derived macrophages.

Authors:  Manjarika De; Anand Bhushan; William S Grubbe; Subhajit Roy; Juan L Mendoza; Sreedhar Chinnaswamy
Journal:  Genes Immun       Date:  2022-02-03       Impact factor: 4.248

5.  Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN-λ3 or IFN-λ4 show distinct phenotypes.

Authors:  Manjarika De; Anand Bhushan; Sreedhar Chinnaswamy
Journal:  J Leukoc Biol       Date:  2020-11-17       Impact factor: 6.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.